medRxiv preprint doi: https://doi.org/10.1101/2022.05.31.22275806; this version posted May 31, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The valve of SHOX2 and RASSF1A gene methylation in bronchoalveolar lavage fluid in the diagnosis of lung cancer

A protocol for systematic review and meta analysis

Shanyang Su[a] , Yanling Huang[a] , Xiang Lu[a] , Wenjia Li[a] , Yongshun Li[a] , Jihong Zhou[a].

Abstract

Introduction: The global incidence of lung cancer is on the rise, and lung cancer remains the cancer with the highest mortality rate in the world. The social burden caused by lung cancer is increasing. Early diagnosis and treatment is the key to improving the five-year survival rate of lung cancer patients, but excessive biopsy and even blind surgery will cause psychological and physical harm to patients. Therefore, it is necessary to find a minimally invasive and effective examination method to improve the survival rate of lung cancer patients. Therefore, the purpose of this systematic review (SR) and meta-analysis will be to analyze and explore the correlation between the promoter methylation of rassF1A and SHOX2 genes and lung cancer, and to provide reference for early clinical diagnosis.

Methods and Analysis: The relevant literature will be comprehensively searched in 4 international electronic databases (PubMed, Cochrane Library, EMBASE and Web of Science) and 4 Chinese electronic databases (CNKI, VIP, Wanfang, Chinese Biomedicine). We only included studies from inception until publication in May 2022. The primary outcome measure was the methylation rate of the SHOX2 and RASSF1A gene promoters in lung cancer tissue and normal lung tissue in the control group in lung cancer patients. Secondary outcome measures included methylation rates of promoters of SHOX2 and RASSF1A genes in different tissue samples. Two reviewers will conduct independent research selection, data extraction, data synthesis and quality assessment. The assessment of bias risk and data synthesis will be conducted using Review Manager 5.3 software. The Cochrane Collaboration's Bias Risk Assessment Tool (QUADAS) will be used to assess the quality of the individual studies included.

Ethics and Dissemination: Because this systematic review will be conducted based on published research, there is no ethical approval requirement. The findings of this systematic review will be published in a peerreviewed journal.

Discussion: This systematic review will help to clarify the correlation between PROMOTER methylation of the RASSF1A and SHOX2 genes with lung cancer, providing clinical evidence for early clinical diagnosis.

Keywords: Lung cancer, DNA methylation , RASSF1A , SHOX2 , meta-analysis, protocol.

1. Introduction.

Primary bronchial lung cancer, referred to as lung cancer, is a malignant tumor that originates from the bronchial mucosa or glands. Lung cancer is insidious, mostly asymptomatic in the early stage, and clinical manifestations such as cough, sputum blood or hemoptysis, shortness of breath, fever, weight loss, chest pain, dyspnea, dysphagia, and hoarseness in the middle and late stages. Due to poor prognosis due to insufficient early diagnosis, studies have shown that the five-year survival rate of lung cancer patients
is only 19.8%. The latest cancer data published by WHO's International Agency for Research on Cancer in 2021 shown that the five-year survival rate of lung cancer patients is only 19.8%. The latest cancer data published by WHO's International Agency for Research on Cancer in 2021 shows that lung cancer remains the cancer with the highest mortality rate. In 2021, there were about 4.82 million new cancer cases and 3.21 million cancer deaths in China. The most common of these is lung cancer, which is the leading cause of cancer death.[1] Lung cancer ranks first in the incidence and mortality of malignant tumors in China. The social burden caused by lung cancer continues to rise, and the situation of prevention and control is grim. With early diagnosis and early intervention, two-thirds of patients can survive for at least 5 years, and some patients may reap long-term survival benefits or even cure lung cancer. [2, 3]

Early diagnosis and early treatment of lung cancer is key to improving the five-year survival rate of lung cancer patients. The detection rate of lung nodules is increasing year by year. Studies have shown that the detection rate of lung nodules in low-dose chest CT physical examination in asymptomatic healthy people is 10.15%[4], and the treatment of lung nodules in modern medicine is mainly based on follow-up review, which is the only treatment measure for lung nodules with high malignancy, but for nodules that cannot determine the nature of good and evil, excessive biopsy and even blind surgery will cause psychological and physiological harm to patients, and also cause waste of social medical resources. It has been reported that 30% of surgically removed lung nodules are benign lesions,[4] and the methods to distinguish benign and malignant diseases are limited, so it is necessary to

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

a : Shenzhen Bao'an Traditional Chinese Medicine Hospital,Guangzhou University of Chinese Medicine

Author: Shanyang Su, professional master's student. Research Interests: Integrative Medicine in the Treatment of Respiratory Diseases. E-mail: 1513235594 @qq.com

Correspondence: Jihong Zhou, Ph.D., Chief Physician, Doctoral Supervisor. Research Interests: Respiratory and Critical Care. The Bao'an District TCM Hospital, The Affiliated Hospital of Guangzhou University of Chinese Medicine, Shenzhen , 518101, Guangdong, China (e-mail: 1620630321@qq.com).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.31.22275806; this version posted May 31, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

find highly sensitive and highly specific detection samples and methods to improve the detection rate of peripheral lung cancer and achieve the purpose of early screening. It has been reported that the cytology of bronchoalveolar lavage fluid in patients with lung cancer can reach 40%.[5]

2. Materials and methods

2.1 Study registration.

Serial number	Search items
#1	Non Small Cell Lung Carcinoma[Mesh]
#2	Carcinoma, Non Small Cell Lung[All Fields]
#3	Carcinomas, Non-Small-Cell Lung[All Fields]
#4	Lung Carcinoma, Non-Small-Cell[All Fields]
#5	Lung Carcinomas, Non-Small-Cell[All Fields]
#6	Non-Small-Cell Lung Carcinomas[All Fields]
#7	Non-Small-Cell Lung Carcinoma[All Fields]
#8	Nonsmall Cell Lung Cancer[All Fields]
#9	Carcinoma, Non-Small Cell Lung[All Fields]
#10	Non-Small Cell Lung Carcinoma[All Fields]
#11	Non-Small Cell Lung Cancer[All Fields]
#12	#1 or #2 - #11
#13	Bronchoalveolar Lavage Fluids[Mesh]
#14	Lavage Fluids, Bronchial[All Fields]
#15	Lavage Fluid, Bronchoalveolar[All Fields]
#16	Lavage Fluids, Bronchoalveolar[All Fields]
#17	Bronchial Alveolar Lavage Fluid[All Fields]
#18	Pulmonary Lavage Fluid[All Fields]
#19	Lavage Fluid, Pulmonary[All Fields]
#20	Lavage Fluids, Pulmonary[All Fields]
#21	Pulmonary Lavage Fluids[All Fields]
#22	Lavage Fluid, Bronchial[All Fields]
#23	Lavage Fluid, Lung[All Fields]
#24	Lung Lavage Fluid[All Fields]
#25	Lavage Fluids, Lung[All Fields]
#26	Lung Lavage Fluids[All Fields]
#27	Alveolar Lavage Fluid[All Fields]
#28	Alveolar Lavage Fluids[All Fields]
#29	Lavage Fluid, Alveolar[All Fields]
#30	Lavage Fluids, Alveolar[All Fields]
#31	Bronchial Lavage Fluid[All Fields]
#32	Bronchial Lavage Fluids[All Fields]
#33	#13 or #14 - #32
#34	SHOX2 protein, human[Mesh]
#35	short stature homeobox 2 protein, human[All Fields]
#36	OG12 protein, human[All Fields]
#37	OGI2X protein, human[All Fields]
#38	#34 or #35 - #37
#39	RASSF1 protein, human[Mesh]
#40	Ras association (RalGDS-AF-6) domain family 1 protein, human[All Fields]
#41	RASSF1B protein, human[All Fields]
#42	RASSF1C protein, human[All Fields]
#43	#39 or #40 - #42
#44	#12 and #33 and #38 and #43

Table 1 : Search strategy in PubMed.

The study protocol has been registered in PROSPERO (registration number: CRD42022330609). Evaluation reports will be conducted in accordance with the preferred reporting items in the systematic review and meta-analysis guidelines.

2.2 Study design

2.2.1 Type of participants. Lung cancer patients, patients with benign lung tumors (with a clear pathological diagnosis), and normal people will be included. There are no restrictions on gender, race, curriculum, ethnicity or country. Eligibility criteria: complete bronchoalveolar lavage fluid SHOX2, RASSF1A test with test results, with clear tissue and /or cell pathological results.)

2.2.2 Type of interventions. Because this is a diagnostic meta, there are no interventions.

2.2.3 Types of outcome measures. The primary outcome will include methylation rates of SHOX2 and RASSF1A gene promoters in lung cancer tissues of patients with lung cancer and normal lung tissues of control group. Secondary outcome will include methylation rates of SHOX2 and RASSF1A gene promoters in the different tissue samples.

2.2.4 Inclusion and exclusion criteri. Studies that met all of the following requirements will be included:

(1) Diagnosis: Lung cancer patients diagnosed with pathological diagnosis are the case group, and non-lung cancer patients (benign diseases or healthy people) are the control group;

(2) Diagnostic method: The test to be evaluated is bronchoalveolar lavage fluid SHOX2, RASSF1A detection to diagnose lung cancer, with pathological diagnosis as the gold standard;

(3) Participants were diagnosed with pulmonary nodules by clinicians based on diagnostic criteria in the original study;

At the same time, for multiple reports of the same study, we only include the most recent reports.

Studies that met one of the following requirements will be excluded:

(1) Incomplete diagnostic data cannot be obtained;

(2) Repeated publication and repeated detection;

(3) Incomplete data cannot be extracted;

(4) Case reports, animal experiments, qualitative studies, reviews or review articles.

2.3 Literature search strategy.

We will search articles in four international electronic databases (PubMed, Cochrane Library, EMBASE, and Web of Science) and 4 Chinese electronic databases (China National Knowledge Infrastructure, VIP, Wanfang, and China Biology Medicine).All the publications until 30 April 2022 will be searched without any restriction of countries or article type. These studies must be published in English or Chinese. Reference list of all selected articles will independently screened to identify additional studies left out in the initial search. The literature search will be structured around search terms such as "non-small cell lung cancer, SHOX2 protein, human, RASSF1 protein, human, Bronchoalveolar Lavage Fluids" and adjust each database as needed. PubMed's detailed search strategy is shown in Table 1. The search policy will also be used for any other electronic databases.

2.4 Study selection.

In the first step of the data processing process, the retrieval strategy retrieves the titles and abstracts of all studies that are filtered for relevance, and the titles and abstracts of all studies that are clearly irrelevant will be discarded. If the results are not obviously irrelevant, the full text will be downloaded. In the second step, two members of the evaluation panel (Shanyang Su , Yanling Huang) will independently assess the eligibility of the study using the redefined inclusion and exclusion criteria. In addition, for studies that meet the inclusion criteria, reviewers will read the entire article to ensure that the entire study meets the criteria and are prepared to extract relevant information. Any disagreements on whether to include a particular study will be resolved through discussions between reviewers.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.31.22275806; this version posted May 31, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

(with a third author if necessary) to identify and resolve. For data on the missing part, we will contact the study authors for the missing data. The flowchart of all study selection procedures is shown in Figure 1.

2.5 Data extraction.

The information extracted by the 2 review team members from the relevant literature will include the first author name, study location, title, journal name, publication year, study environment, study population and participant demographics and baseline characteristics, detection methods, sample size included, methylation rate of promoters of shox2 and RASSF1A genes, number of SHOX2 positive cases, number of RASSF1A positive cases, number of SHOX2 and RASSF1A double positive cases, etc. used to assess the risk of bias. Two reviewers will extract the data independently; Discrepancies will be identified and resolved through discussion. If important data are missing, we will ask the study authors to provide the number of missing data.

2.6 Risk of bias Assessment.

The bias risk assessment will involve 2 evaluators in the quality assessment process and any significant differences will be resolved through discussions to determine the final set of studies to be included. The two reviewers independently assessed the risk of bias in the included studies by taking into account the following characteristics: participant representation, gold standard reasonableness, intervals between trials, gold standard blind assessment, uncertain results and other sources of bias. In addition, the Cochrane Collaboration's Bias Risk Assessment Tool (QUADAS) will be used to assess the quality of individual studies included.

2.7 Data synthesis.

We will use Review Manager 5.3 software to carry out the quantitative synthesis if the included studies are sufficiently homogeneous. Mean difference or standardized means difference will be used for continuous data. Odds ratio (OR) will be used for the analysis of dichotomous data. Both we will give a 95% confidence interval (CI). In the case of homogeneous data, if I2≤50%, the fixed-effect model will be adopted for the meta-analysis. Otherwise, the sources of heterogeneity will be further analyzed. After excluding marked clinical heterogeneity, a random-effect model will be adopted to perform the meta-analysis. Sensitivity and bias risk analyses will also be performed.

2.7.1. Analysis of subgroups. There are some planned subgroup analyses will be performed: different tissue samples of lung cancer (eg: tissue, BLAF, serum and pleural effusion), different pathological types of lung cancer (eg: squamous cell carcinoma and adenocarcinoma)

2.7.2. Sensitivity analysis. Sensitivity analysis will be performed to determine the stability of the aggregated results by reducing 1 document at a time.

2.7.3. Reporting bias analysis. Apply Stata 14.0 software to draw Deek's funnel diagrams to identify publication bias in literature. Test level α=0.05. The rate parameter P<0.05, is considered to be publication biased

2.8. Quality of evidence

The Cochrane Collaboration's Bias Risk Assessment Tool (QUADAS) will be used to assess the quality of the individual studies included.

2.9. Patient and Public Involvement

Patients or the public WERE NOT involved in the design, or conduct, or reporting, or dissemination plans of our research

3. Ethics and dissemination.

Because this systematic review will be conducted based on published research, there is no ethical approval requirement. The findings of this systematic review will be published in a peerreviewed journal.

4. Discussion.

The occurrence of lung cancer is a complex process of multi-gene participation and multi-stage gradual evolution. The activation of oncogenes and the inactivation of tumor suppressors are closely related to the occurrence and development of lung cancer. Studies have found that epigenetics play an important role in the development of tumors. Epigenetics refers to the modification of DNA and histones to influence gene transcription and then regulate gene expression without changing the gene sequence. Gene methylation is a common epigenetic mechanism involved in regulating the occurrence, progression, and metastasis of lung cancer.[6, 7] DNA methylation is currently the most well-studied form of modification in epigenetics. Normal gene methylation is necessary to maintain cell growth and metabolism, while abnormal DNA methylation can trigger diseases such as tumors. There are many changes in the degree of methylation of many unique tumor-related genes (including oncogenes and tumor suppressor genes) in the early stage of lung cancer, so the detection of DNA methylation is of great significance for the early diagnosis of cancer.

SHOX2 is a member of the homologous box gene family that regulates gene expression and controller geneogenesis and cell differentiation. RASSF1A is an important tumor suppressor gene that mediates apoptosis by binding to cells, and hypermethylation of its promoter CpG island is one of the important mechanisms for inactivation of the RASSF1A gene.[8] RASSF1A is closely linked to the occurrence and development of a variety of malignant tumors, is a novel tumor suppressor gene, and RASSF1A is one of the most methylated and common genes in tumors.[4]

Abnormal methylation of the DNA gene promoter can be detected in a variety of malignancies and is expected to be a marker for early diagnosis. Studies have shown that the methylation of tumor suppressor genes such as short stature home-obox 2 (SHOX2) and RAS-related regional family 1A (RASSF1A) is closely related to the early diagnosis of lung cancer, and multi-gene combination detection is better than single gene,[9] and this study takes the tumor suppressor genes RASSF1A and SHOX2 as examples. Comprehensive collection of clinical studies between RASSF1A, SHOX2 gene methylation and lung cancer. The correlation between promoter methylation of RASSF1A and SHOX2 genes and lung cancer was explored by meta-analysis, which provided a reference for early clinical diagnosis.

5. Author contributions

Conceptualization: Shanyang Su , Yanling Huang , Xiang Lu , Wenjia Li , Yongshun Li , Jihong Zhou.
Data curation: Xiang Lu, Jihong Zhou.
Formal analysis: Shanyang Su , Yanling Huang.
Methodology: Shanyang Su , Yanling Huang,Jihong Zhou..
Project administration:. Yongshun Li,Jihong Zhou.
Resources: Shanyang Su, Jihong Zhou.
Software: Shanyang Su, Yanling Huang.
Visualization: Xiang Lu , Wenjia Li.
Writing – original draft: Shanyang Su , Yanling Huang , Xiang Lu

medRxiv preprint doi: https://doi.org/10.1101/2022.05.31.22275806; this version posted May 31, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Writing – review & editing: Yongshun Li, Jihong Zhou ,

Xiang Lu

6. Funding Statement

The authors report no conflicts of interest.

7. Conflict of Interests Statement

This research didn't receive grants from any funding agency in the public, commercial or not-for-profit sectors.

References:

[1]. Xia, C., et al., Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl), 2022. 135(5): p. 584-590.

[2]. Brody, H., Lung cancer. Nature, 2020. 587(7834): p. S7.

[3]. Da, C.D., et al., Lung Cancer: Advances and Insights in Diagnosis, Treatment, and Palliation. Am J Respir Crit Care Med, 2018. 198(5): p. 667-669.

[4]. Zhang, C., et al., DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis. J Cancer, 2017. 8(17): p. 3585-3591.

[5]. Henschke, C.I., et al., Survival of patients with stage I lung cancer detected on CT screening. The New England journal of medicine, 2006. 355(17).

[6]. Koch, A., et al., Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncol, 2018. 15(7): p. 459-466.

[7]. Belinsky, S.A., Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer, 2004. 4(9): p. 707-17.

[8]. Deng, Q., et al., Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy. Cancer Biomark, 2020. 27(3): p. 313-323.

[9]. Song, L., H. Yu and Y. Li, Diagnosis of Lung Cancer by SHOX2 Gene Methylation Assay. Mol Diagn Ther, 2015. 19(3): p. 159-67.

Figure 1：Flowchart of study selection procedures